Backed by science
Amberen is deeply committed to scientific research and innovation, allowing us to develop clinically proven formulas that deliver maximum relief for as many women as possible.
Trust the experts
Meet a few of the science and medical professionals who support Amberen's thorough product research and testing.
Dr. Vera Kachko
MD, PhD Endocrinology & Oncology
Amberen Scientific Advisor
Dr. Anna Skylar
PhD Molecular Biology
Amberen Scientific Affairs
Dr. Aliki Kana-Edwards
PhD Chemistry
Senior Technical Research & Development Manager
Dr. Phil Barry
PhD Biochemistry
Clinical Research & Development Manager
Amberen's history
Learn about some of our many scientific achievements and milestones over the years.
1971
Small doses of amber (succinic) acid were used to rejuvenate the hypothalamus by restoring its sensitivity.
1978
In pre-clinical trials, succinic acid showed to improve menopausal changes and also exhibited very distinct signs of rejuvenation.
1999
Enerlit-Clima (equivalent of Amberen’s formulation) composition was developed. In preclinical trials, the supplement was shown to be safe (no acute or long-term toxicity) and to be effective for the alleviation of more than 12 menopausal symptoms.
2001
A placebo-controlled study demonstrated that Enerlit-Clima-based therapy helps alleviate many menopause symptoms when compared with the placebo group. No adverse side effects when taking Enerlit-Clima were registered.
2004
A 3-year-long observational clinical study was conducted. Enerlit-Clima (equivalent of Amberen’s formulation) was shown to be safe and effective when it came to managing several menopausal symptoms.
2016
A 12-week study demonstrated that Amberen Menopause Relief was a safe and well-tolerated supplement with no adverse side effects. Compared to the placebo group, women who took Amberen reported significant improvements in many menopausal symptoms.
2020
A 180-day study demonstrated that Amberen Perimenopause Relief was a safe and well-tolerated supplement with no adverse side effects. Compared to the placebo group, women who took Amberen reported significant improvements in many perimenopause symptoms.